UBS Adjusts Price Target on Zimmer Biomet to $120 From $115, Maintains Buy Rating

UBS has increased its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $120 from $115, while reaffirming a Buy rating on the stock. This adjustment comes amidst other analyst revisions for Zimmer Biomet on the same day, indicating active re-evaluation of the company's financial outlook by various firms. The company specializes in orthopedic reconstruction implants and traumatology products.